TDMS Study 05087-02 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
TRIAMTERENE
NTP Experiment-Test: 05087-02 Report: PEIRPT05
Study Type: CHRONIC Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
Facility: Battelle Columbus Laboratory
Chemical CAS #: 396-01-0
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 70 70 70
Scheduled Sacrifice 20 20 20 10
Early Deaths
Moribund Sacrifice 8 5 1 10
Natural Death 4 2 6 7
Survivors
Terminal Sacrifice 37 41 42 43
Moribund Sacrifice 1
Natural Death 1 1 1
Animals Examined Microscopically 70 62 60 70
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (67) (47) (58) (65)
Intestine Large, Cecum (67) (50) (59) (70)
Intestine Small, Ileum (67) (49) (59) (67)
Intestine Small, Jejunum (67) (48) (58) (69)
Adenocarcinoma 1 (1%)
Liver (70) (52) (60) (70)
Hemangiosarcoma 1 (1%) 1 (2%)
Hepatocellular Carcinoma 3 (4%) 3 (6%) 3 (5%) 6 (9%)
Hepatocellular Carcinoma, Multiple 1 (1%) 1 (2%) 2 (3%)
Hepatocellular Adenoma 8 (11%) 12 (23%) 14 (23%) 22 (31%)
Hepatocellular Adenoma, Multiple 4 (6%) 12 (23%) 11 (18%) 14 (20%)
Hepatocholangiocarcinoma 1 (1%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Serosa, Adenocarcinoma, Metastatic, Ovary 1 (2%)
Mesentery (8) (10) (8) (5)
Adenocarcinoma, Metastatic, Ovary 1 (10%)
Hemangiosarcoma 1 (13%)
Hepatocholangiocarcinoma, Metastatic, Uterus 1 (13%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (20%)
Pancreas (69) (50) (60) (70)
Adenocarcinoma, Metastatic, Ovary 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Uterus 1 (1%)
Salivary Glands (69) (49) (60) (70)
Stomach, Forestomach (69) (50) (60) (70)
Squamous Cell Carcinoma 1 (2%)
Squamous Cell Papilloma 1 (2%) 1 (1%)
____________________________________________________________________________________________________________________________________
Page 2
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (70) (50) (60) (70)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (70) (50) (60) (70)
Spindle Cell, Adenoma 3 (4%) 3 (5%) 2 (3%)
Islets, Pancreatic (69) (49) (60) (69)
Adenoma 1 (2%)
Pituitary Gland (68) (47) (57) (68)
Pars Distalis, Adenoma 7 (10%) 5 (11%) 3 (5%) 5 (7%)
Pars Intermedia, Adenoma 2 (4%) 1 (1%)
Thyroid Gland (69) (49) (60) (70)
Follicular Cell, Adenoma 1 (1%) 1 (2%) 1 (2%) 1 (1%)
Follicular Cell, Carcinoma 1 (1%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (68) (54) (60) (69)
Adenocarcinoma 1 (2%)
Cystadenoma 1 (1%) 1 (2%) 1 (2%) 1 (1%)
Granulosa Cell Tumor Benign 1 (2%)
Hemangiosarcoma 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Uterus 1 (1%)
Mixed Tumor Benign 1 (1%)
Teratoma 1 (1%)
Uterus (68) (54) (60) (70)
Adenoma 2 (4%)
Hemangiosarcoma 1 (2%)
Polyp Stromal 1 (2%) 2 (3%) 2 (3%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (70) (50) (60) (70)
Hemangiosarcoma 1 (2%) 1 (2%) 1 (1%)
Lymph Node (69) (50) (60) (70)
Axillary, Liposarcoma, Metastatic, Skin 1 (2%)
Inguinal, Squamous Cell Carcinoma,
Metastatic, Skin 1 (1%)
Page 3
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - cont
Mediastinal, Hepatocellular Carcinoma,
Metastatic, Liver 1 (2%)
Mediastinal, Hepatocholangiocarcinoma,
Metastatic, Uterus 1 (1%)
Renal, Hepatocholangiocarcinoma, Metastatic,
Uterus 1 (1%)
Lymph Node, Mandibular (66) (49) (59) (68)
Adenocarcinoma, Metastatic, Ovary 1 (2%)
Lymph Node, Mesenteric (61) (45) (55) (64)
Hepatocholangiocarcinoma, Metastatic, Uterus 1 (2%)
Spleen (69) (50) (58) (70)
Hemangiosarcoma 1 (1%) 3 (5%) 1 (1%)
Thymus (58) (44) (53) (60)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (55) (43) (53) (61)
Skin (70) (49) (59) (70)
Basal Cell Carcinoma 1 (1%)
Squamous Cell Carcinoma 1 (1%)
Subcutaneous Tissue, Fibrosarcoma 3 (4%) 1 (2%) 3 (4%)
Subcutaneous Tissue, Hemangioma 1 (2%)
Subcutaneous Tissue, Hemangiosarcoma 1 (1%)
Subcutaneous Tissue, Liposarcoma 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (70) (50) (60) (70)
Vertebra, Osteosarcoma 1 (2%) 1 (2%)
Skeletal Muscle (1) (1)
Adenocarcinoma, Metastatic, Ovary 1 (100%)
Hepatocholangiocarcinoma, Metastatic, Uterus 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
None
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (70) (50) (60) (70)
Adenocarcinoma, Metastatic, Ovary 1 (2%)
Alveolar/Bronchiolar Adenoma 5 (7%) 5 (10%) 2 (3%) 1 (1%)
Alveolar/Bronchiolar Carcinoma 1 (2%) 3 (4%)
Page 4
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM - cont
Hepatocellular Carcinoma, Metastatic, Liver 1 (1%) 1 (2%) 1 (2%)
Hepatocholangiocarcinoma, Metastatic, Uterus 1 (1%)
Liposarcoma, Multiple, Metastatic, Skin 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%) 1 (2%)
Osteosarcoma, Metastatic, Uncertain Primary
Site 1 (1%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (3) (3) (2)
Adenoma 1 (100%) 3 (100%) 2 (67%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (70) (61) (60) (70)
Capsule, Adenocarcinoma, Metastatic, Ovary 1 (2%)
Urinary Bladder (68) (49) (59) (70)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(70) *(62) *(60) *(70)
Lymphoma Malignant Histiocytic 1 (1%) 3 (5%) 5 (8%) 3 (4%)
Lymphoma Malignant Lymphocytic 2 (3%) 1 (2%) 2 (3%)
Lymphoma Malignant Mixed 9 (13%) 5 (8%) 9 (15%) 6 (9%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 5
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 37 42 43 46
Total Primary Neoplasms 56 62 70 81
Total Animals with Benign Neoplasms 25 33 30 36
Total Benign Neoplasms 31 44 43 51
Total Animals with Malignant Neoplasms 20 17 22 25
Total Malignant Neoplasms 25 18 27 30
Total Animals with Metastatic Neoplasms 2 4 2 2
Total Metastatic Neoplasm 9 11 4 3
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 6
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 70 70 70 70
Scheduled Sacrifice 20 20 20 10
Early Deaths
Natural Death 2 3 2 8
Moribund Sacrifice 1 2 2 6
Survivors
Terminal Sacrifice 47 45 46 46
Animals Examined Microscopically 70 64 61 70
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (67) (46) (60) (64)
Intestine Large, Cecum (70) (50) (60) (63)
Intestine Large, Colon (69) (49) (60) (67)
Intestine Small, Duodenum (70) (50) (59) (65)
Adenocarcinoma 1 (2%)
Intestine Small, Ileum (69) (49) (59) (65)
Intestine Small, Jejunum (70) (50) (59) (65)
Adenocarcinoma 1 (2%)
Liver (70) (53) (60) (70)
Hemangiosarcoma 1 (1%) 1 (2%) 3 (5%)
Hepatoblastoma 1 (2%) 1 (2%)
Hepatocellular Carcinoma 4 (6%) 7 (13%) 3 (5%) 13 (19%)
Hepatocellular Carcinoma, Multiple 1 (1%)
Hepatocellular Adenoma 14 (20%) 14 (26%) 13 (22%) 9 (13%)
Hepatocellular Adenoma, Multiple 4 (6%) 11 (21%) 8 (13%) 11 (16%)
Mesentery (3) (3) (4) (2)
Pancreas (70) (50) (60) (70)
Stomach, Forestomach (69) (50) (60) (68)
Squamous Cell Papilloma 1 (1%)
Stomach, Glandular (70) (50) (60) (69)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
None
____________________________________________________________________________________________________________________________________
Page 7
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (70) (50) (60) (69)
Capsule, Adenoma 1 (1%)
Adrenal Gland, Medulla (69) (50) (58) (70)
Pheochromocytoma Malignant 1 (2%)
Thyroid Gland (70) (50) (60) (70)
C-Cell, Adenoma 1 (2%)
Follicular Cell, Adenoma 1 (2%) 1 (2%) 2 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (70) (50) (60) (70)
Prostate (70) (50) (60) (70)
Seminal Vesicle (60) (50) (60) (60)
Testes (70) (50) (60) (70)
Interstitial Cell, Adenoma 1 (2%) 1 (1%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (69) (50) (60) (70)
Lymph Node (70) (50) (60) (70)
Lymph Node, Mandibular (67) (48) (59) (70)
Lymph Node, Mesenteric (62) (46) (53) (55)
Spleen (70) (50) (60) (70)
Hemangioma 1 (2%)
Hemangiosarcoma 1 (2%) 2 (3%)
Thymus (56) (40) (46) (49)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (69) (50) (59) (70)
Subcutaneous Tissue, Fibroma 1 (1%)
Subcutaneous Tissue, Hemangioma 1 (2%)
____________________________________________________________________________________________________________________________________
Page 8
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (69) (50) (60) (69)
Femur, Hemangiosarcoma, Metastatic, Spleen 1 (2%)
Skeletal Muscle (1) (2) (1)
Alveolar/Bronchiolar Carcinoma, Metastatic,
Lung 1 (50%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (70) (50) (60) (70)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (70) (51) (60) (70)
Adenocarcinoma, Metastatic, Harderian Gland 1 (1%)
Alveolar/Bronchiolar Adenoma 5 (7%) 10 (20%) 9 (15%) 9 (13%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%)
Alveolar/Bronchiolar Carcinoma 4 (6%) 1 (2%) 4 (7%) 4 (6%)
Alveolar/Bronchiolar Carcinoma, Multiple 2 (3%) 2 (4%) 2 (3%) 1 (1%)
Nose (70) (50) (60) (70)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (3) (3) (6) (2)
Adenocarcinoma 1 (33%) 1 (50%)
Adenoma 1 (33%) 3 (50%) 1 (50%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (70) (64) (61) (70)
Urinary Bladder (70) (50) (59) (70)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(70) *(64) *(61) *(70)
Lymphoma Malignant Histiocytic 1 (2%) 1 (1%)
Lymphoma Malignant Lymphocytic 1 (1%)
Lymphoma Malignant Mixed 5 (7%) 3 (5%) 4 (7%) 4 (6%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 9
NTP Experiment-Test: 05087-02 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC TRIAMTERENE Date: 09/11/94
Route: DOSED FEED Time: 13:32:16
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0PPM 100PPM 200PPM 400PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 35 42 37 38
Total Primary Neoplasms 44 56 57 60
Total Animals with Benign Neoplasms 24 30 31 27
Total Benign Neoplasms 25 39 37 34
Total Animals with Malignant Neoplasms 17 17 16 22
Total Malignant Neoplasms 19 17 20 26
Total Animals with Metastatic Neoplasms 1 1 1
Total Metastatic Neoplasm 1 2 1
Total Animals with Malignant Neoplasms
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 10
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------